|
|
Conmed Corporation (NYSE: CNMD) |
|
Price: $67.6900
$0.83 
1.241%
|
| Day's High:
| $68.245
| Week Perf:
| -2.6 %
|
| Day's Low: |
$ 66.38 |
30 Day Perf: |
-5.09 % |
| Volume (M): |
398 |
52 Wk High: |
$ 103.81 |
| Volume (M$): |
$ 26,947 |
52 Wk Avg: |
$73.32 |
| Open: |
$67.21 |
52 Wk Low: |
$61.05 |
|
|
| Market Capitalization (Millions $) |
2,106 |
| Shares
Outstanding (Millions) |
31 |
| Employees |
4,000 |
| Revenues (TTM) (Millions $) |
1,288 |
| Net Income (TTM) (Millions $) |
132 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
14 |
Conmed Corporation
Conmed Corporation is a global medical technology company that specializes in the development, manufacturing, and sales of surgical devices and equipment. The company's products are used in surgical procedures across several medical specialties, including orthopedics, gastroenterology, gynecology, respiratory therapy, and cardiology.
Conmed Corporation was founded in 1970 in Utica, New York. The company has since expanded its operations globally with offices throughout North America, Europe, and Asia. Its headquarters are in Utica, New York.
The company's product offerings include a vast range of surgical instruments, electrosurgical systems, patient monitoring equipment, endoscopy equipment, and imaging systems. They aim to develop innovative solutions to address the needs of healthcare professionals around the world.
Conmed is also known for its advanced energy products that are used in surgical procedures. The company's energy products range from generators and surgical instruments to accessories like medical tapes, electrodes, and connectors. Conmed's EDGE Technology is one of the latest advancements in surgical technology, utilizing both radiofrequency and ultrasound energy to deliver precise and efficient results.
In recent years, Conmed has acquired several companies, including SurgiQuest, Buffalo Filter, and Westmed. These acquisitions have allowed the company to expand its product offerings and solidify its position as a major player in the medical technology industry.
In addition to its core product offerings, Conmed also provides educational resources to healthcare professionals through its Clinical Education Department. The department conducts training sessions, seminars, and workshops to help healthcare professionals stay up-to-date on the latest surgical techniques and innovations.
Conmed has received several awards and recognitions for its innovative products, including the Medical Design Excellence Award, the Clinician's Choice Award, and the Frost & Sullivan Product Innovation Award.
The company is committed to sustainability and reducing its environmental impact. Conmed has implemented various initiatives to reduce waste, energy consumption, and greenhouse gas emissions. They also have a program in place for recycling medical devices and instruments.
Overall, Conmed Corporation is a leading medical technology company that continues to drive innovation in the surgical industry. With a wide range of products and a commitment to sustainability, the company is well-positioned for continued growth and success.
Company Address: 11311 Concept Blvd Largo, 33773 FL
Company Phone Number: 392-6464 Stock Exchange / Ticker: NYSE CNMD
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Dividend
Published Mon, Aug 12 2024 2:00 PM UTC
CONMED Corporation: A Steady Dividend Policy Amid Rising Earnings
LARGO, Fla. In a significant announcement today, CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share, set to be paid out on October 4, 2024. This decision, made by the Company s Board of Directors, applies to all shareholders on record as of September 16, 2024...
|
| Dividend
Published Sun, Aug 11 2024 5:42 PM UTC
Press Release: CONMED Corporation Announces Quarterly Cash Dividend and Positive Outlook
CONMED Corporation, a leading medical technology company specializing in surgical devices and equipment, has recently declared a quarterly cash dividend of $0.20 per share. This announcement comes as a positive development for the company s shareholders, underscoring its commitment t...
|
| Conmed Corporation
Breaking News: CONMED Corporation Declares Quarterly Dividend Amid Strong Financial Performance
LARGO, Fla. - In a recent press release, CONMED Corporation (NYSE: CNMD), a leading medical technology company, announced its financial results for the fourth quarter and full-year ended December 31, 2023. The company reported impressive figures, with sales reaching $327.0 million, marking a significant 30.4% year-over-year increase. Diluted net earnings per share were reported at $1.05, further highlighting CONMED's robust financial performance.
To the delight of its shareholders, CONMED also declared a quarterly cash dividend of $0.20 per share. The dividend payout is set to occur on April 5, 2024, and shareholders of record by March 15, 2024, will be eligible to receive it. This declaration reinforces CONMED's commitment to rewarding shareholders and signifies the company's confidence in its financial standing and ability to consistently generate returns.
|
| Conmed Corporation
As a financial journalist covering the latest developments in the market, it is my duty to provide a comprehensive analysis of the recent financial results announced by Conmed Corporation (NYSE: CNMD). Despite the company's positive performance in terms of income growth, EPS elevation, and revenue jumps, it is crucial to shed light on the recent decline in Conmed Corporation's shares.
In the financial interval closing December 31, 2023, Conmed Corporation reported a substantial increase in income, with a growth of 17.88% from $0.87 to $1.02 per share compared to the previous year. Additionally, the EPS saw a remarkable leap of 104.85% from $0.50 per share in the prior reporting season. These figures undoubtedly indicate the growing profitability of the company and its ability to generate higher returns for its shareholders.
|
| Dividend
Published Tue, Feb 27 2024 9:05 PM UTC
In a recent press release, CONMED Corporation (NYSE: CNMD), a leading medical technology company, has declared a quarterly cash dividend of $0.20 per share. This announcement comes as a testament to the company s robust financial performance and commitment to rewarding its shareholders. With a wide range of surgical devices and equipment for minimally invasive proc...
|
| Per Share |
Current |
| Earnings (TTM) |
4.18 $ |
| Revenues (TTM) |
41.4 $
|
| Cash Flow (TTM) |
0.26 $ |
| Cash |
-
|
| Book Value |
29.99 $
|
| Dividend (TTM) |
0.79 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
4.18 $
|
| Revenues (TTM) |
41.4 $ |
| Cash Flow (TTM) |
0.26 $ |
| Cash |
-
|
| Book Value |
29.99 $ |
| Dividend (TTM) |
0.79 $ |
|
|
| |
| Goods transferred at a point in time |
|
 96.14 % |
of total Revenue |
| Services transferred over time |
|
3.86 % |
of total Revenue |
| Orthopedic Surgery |
|
41.22 % |
of total Revenue |
| Orthopedic Surgery Goods transferred at a point in time |
|
38.06 % |
of total Revenue |
| Orthopedic Surgery Services transferred over time |
|
3.16 % |
of total Revenue |
| General Surgery |
|
58.78 % |
of total Revenue |
| General Surgery Goods transferred at a point in time |
|
58.08 % |
of total Revenue |
| General Surgery Services transferred over time |
|
0.71 % |
of total Revenue |
| United States |
|
57.83 % |
of total Revenue |
| United States Orthopedic Surgery |
|
15.69 % |
of total Revenue |
| United States General Surgery |
|
42.14 % |
of total Revenue |
| Americas excluding the United States |
|
9.1 % |
of total Revenue |
| Americas excluding the United States Orthopedic Surgery |
|
6.07 % |
of total Revenue |
| Americas excluding the United States General Surgery |
|
3.03 % |
of total Revenue |
| Europe Middle East Africa |
|
17.53 % |
of total Revenue |
| Europe Middle East Africa Orthopedic Surgery |
|
9.09 % |
of total Revenue |
| Europe Middle East Africa General Surgery |
|
8.44 % |
of total Revenue |
| Asia Pacific |
|
15.54 % |
of total Revenue |
| Asia Pacific Orthopedic Surgery |
|
10.36 % |
of total Revenue |
| Asia Pacific General Surgery |
|
5.17 % |
of total Revenue |
| |
On October 7 2024 the Conmed provided following guidance
nnCONMED Corporation Releases Preliminary Financial Projections for Third Quarter 2024nn
LARGO, Fla. ? Following up on its Current Report on Form 8-K issued on September 30, 2024, CONMED Corporation (NYSE: CNMD) has announced preliminary financial estimates for the third quarter of fiscal year 2024. The company anticipates revenues to be between $315 million and $318 million.
In addition, CONMED is projecting that its adjusted diluted net earnings per share will grow at a rate surpassing its prior forecast of 9% to 11%. This upward revision reflects the company?s strong performance during the quarter, underlining its ongoing success and resilience in the medical devices sector.
A ...
|
|
|
4.28% 